BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37686409)

  • 1. The Prognosis-Predictive and Immunoregulatory Role of SUMOylation Related Genes: Potential Novel Targets in Prostate Cancer Treatment.
    Sun JX; An Y; Xiang JC; Xu JZ; Hu J; Wang SG; Xia QD
    Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SUMOylation Pattern Predicts Prognosis and Indicates Tumor Microenvironment Infiltration Characterization in Bladder Cancer.
    Xia QD; Sun JX; Xun Y; Xiao J; Liu CQ; Xu JZ; An Y; Xu MY; Liu Z; Wang SG; Hu J
    Front Immunol; 2022; 13():864156. PubMed ID: 35418978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel senescence-associated signature to predict biochemical recurrence and immune microenvironment for prostate cancer.
    Han C; Deng Y; Yang B; Hu P; Hu B; Wang T; Liu J; Xia Q; Liu X
    Front Immunol; 2023; 14():1126902. PubMed ID: 36891298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing.
    Li T; Zhou Z; Xie Z; Fan X; Zhang Y; Zhang Y; Song X; Ruan Y
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11379-11395. PubMed ID: 37369799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer.
    Luo C; Chen J; Chen L
    Int Immunopharmacol; 2020 Sep; 86():106709. PubMed ID: 32593155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer.
    Wang L; Yao Y; Xu C; Wang X; Wu D; Hong Z
    Technol Cancer Res Treat; 2021; 20():15330338211052154. PubMed ID: 34806485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cuproptosis illustrates tumor micro-environment features and predicts prostate cancer therapeutic sensitivity and prognosis.
    Cheng B; Tang C; Xie J; Zhou Q; Luo T; Wang Q; Huang H
    Life Sci; 2023 Jul; 325():121659. PubMed ID: 37011878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction and validation of a fatty acid metabolism-related gene signature for predicting prognosis and therapeutic response in patients with prostate cancer.
    Zhao H; Wu T; Luo Z; Huang Q; Zhu S; Li C; Zhang Z; Zhang J; Zeng J; Zhang Y
    PeerJ; 2023; 11():e14854. PubMed ID: 36778142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EZH2 as a Prognostic Factor and Its Immune Implication with Molecular Characterization in Prostate Cancer: An Integrated Multi-Omics in Silico Analysis.
    Du TQ; Liu R; Zhang Q; Luo H; Liu Z; Sun S; Wang X
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tertiary lymphoid structure patterns aid in identification of tumor microenvironment infiltration and selection of therapeutic agents in bladder cancer.
    An Y; Sun JX; Xu MY; Xu JZ; Ma SY; Liu CQ; Liu Z; Wang SG; Xia QD
    Front Immunol; 2022; 13():1049884. PubMed ID: 36420257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a Pyroptosis-Related Signature for Prognosis Prediction and Immune Microenvironment Infiltration in Prostate Cancer.
    Zhang G; Luo Y; Dong W; Zhong W
    Comput Math Methods Med; 2022; 2022():8233840. PubMed ID: 35516457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
    Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
    Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
    Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
    Front Immunol; 2022; 13():943389. PubMed ID: 36003381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a Novel Nomogram to Predict Progression Based on the Circadian Clock and Insights Into the Tumor Immune Microenvironment in Prostate Cancer.
    Feng D; Xiong Q; Zhang F; Shi X; Xu H; Wei W; Ai J; Yang L
    Front Immunol; 2022; 13():777724. PubMed ID: 35154101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of the biological functions of endoplasmic reticulum stress in prostate cancer.
    Cen S; Jiang D; Lv D; Xu R; Hou J; Yang Z; Wu P; Xiong X; Gao X
    Front Endocrinol (Lausanne); 2023; 14():1090277. PubMed ID: 36967783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma cell subtypes analyzed using artificial intelligence algorithm for predicting biochemical recurrence, immune escape potential, and immunotherapy response of prostate cancer.
    Xie X; Dou CX; Luo MR; Zhang K; Liu Y; Zhou JW; Huang ZP; Xue KY; Liang HY; Ouyang AR; Ma SX; Yang JK; Zhou QZ; Guo WB; Liu CD; Zhao SC; Chen MK
    Front Immunol; 2022; 13():946209. PubMed ID: 36569837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
    Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
    Front Genet; 2022; 13():919389. PubMed ID: 35783281
    [No Abstract]   [Full Text] [Related]  

  • 18. The Senescence-Related Signature Predicts Prognosis and Characterization of Tumor Microenvironment Infiltration in Pancreatic Cancer.
    Hua H; Zheng C; Fan J; Li X; Xie W; Chen J; Yu C
    Biomed Res Int; 2022; 2022():1916787. PubMed ID: 36518628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-omics analysis reveals a macrophage-related marker gene signature for prognostic prediction, immune landscape, genomic heterogeneity, and drug choices in prostate cancer.
    Zhu W; Wu J; Huang J; Xiao D; Li F; Wu C; Li X; Zeng H; Zheng J; Lai W; Wen X
    Front Immunol; 2023; 14():1122670. PubMed ID: 37122696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of an age- and tumor microenvironment-related gene signature for survival prediction in prostate cancer.
    Chen L; Zhang M; Zhou J; Zhang L; Liang C
    Cancer Med; 2022 Nov; 11(22):4374-4388. PubMed ID: 35535438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.